<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250319001344&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250319001344&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 19 Mar 2025 04:13:45 +0000</lastbuilddate>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Left atrial intramural hematoma after ventricular radiofrequency catheter ablation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40101156/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Cardiovasc Imaging. 2025 Mar 18:jeaf091. doi: 10.1093/ehjci/jeaf091. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40101156/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40101156</a> | DOI:<a href=https://doi.org/10.1093/ehjci/jeaf091>10.1093/ehjci/jeaf091</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40101156</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Alan Diniz Hummel</dc:creator>
<dc:creator>André Vaz</dc:creator>
<dc:creator>André Paciello Romualdo</dc:creator>
<dc:creator>Andrei Skromov de Albuquerque</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>European heart journal. Cardiovascular Imaging</dc:source>
<dc:title>Left atrial intramural hematoma after ventricular radiofrequency catheter ablation</dc:title>
<dc:identifier>pmid:40101156</dc:identifier>
<dc:identifier>doi:10.1093/ehjci/jeaf091</dc:identifier>
</item>
<item>
<title>Hybrid Versus Percutaneous Left Atrial Decompression in Infants With Hypoplastic Left Heart Variants and an Intact or Highly Restrictive Atrial Septum: A Multicenter PICES Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100953/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with HLH-IAS, hybrid LAD allows for faster atrial septal defect creation, has a higher technical success rate, and potentially fewer procedural serious adverse events compared with percutaneous LAD, alongside facilitating simultaneous pulmonary artery band. Our findings underscore the poor prognosis for patients with HLH-IAS despite intervention, highlighting the need for better treatment strategies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar;18(3):e014243. doi: 10.1161/CIRCINTERVENTIONS.124.014243. Epub 2025 Mar 18.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Neonates with hypoplastic left heart syndrome variants with an intact or highly restrictive atrial septum (HLH-IAS) require immediate postnatal intervention to survive. Emergent left atrial decompression (LAD) via a percutaneous or hybrid approach is standard, but the comparative effectiveness and outcomes of these approaches remain underexplored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A multicenter retrospective analysis of all neonates with HLH-IAS who underwent LAD in the first 36 hours of life from January 2009 to March 2020 at 14 North American congenital cardiac programs was conducted. Patient and procedural characteristics and patient outcomes were compared between hybrid and percutaneous LAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 128 patients with HLH-IAS, 105 (80%) underwent percutaneous LAD and 23 (17%) hybrid LAD. No significant differences were observed in preprocedural characteristics such as birth weight (3.1±0.6 versus 3.2±0.6 kg; <i>P</i>=0.453), presence of a baseline interatrial communication (66% versus 61%; <i>P</i>=0.659), interatrial communication gradient (14.4±6.9 versus 12.7±4.6 mm Hg; <i>P</i>=0.456), or lowest pH (7.13±0.14 versus 7.09±0.15; <i>P</i>=0.193). Hybrid LAD resulted in a shorter time from birth to procedure (120 versus 52 minutes; <i>P</i>=0.005) and to atrial septal defect creation (55 versus 29 minutes; <i>P</i>=0.002). All hybrid LAD were technically successful, although 11 (10%) percutaneous LAD were unsuccessful with 7 requiring conversion to surgical septectomy. There was a trend toward fewer serious adverse events with hybrid LAD (36% versus 17%; <i>P</i>=0.141). Most patients (67%) who underwent hybrid LAD had simultaneous pulmonary artery band placement and 21% of patients with percutaneous LAD required reoperation for pulmonary artery band. Long-term survival rates were comparably low between groups, with a 30% transplant-free survival at a median 8-month follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with HLH-IAS, hybrid LAD allows for faster atrial septal defect creation, has a higher technical success rate, and potentially fewer procedural serious adverse events compared with percutaneous LAD, alongside facilitating simultaneous pulmonary artery band. Our findings underscore the poor prognosis for patients with HLH-IAS despite intervention, highlighting the need for better treatment strategies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100953/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40100953</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014243>10.1161/CIRCINTERVENTIONS.124.014243</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100953</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Konstantin Averin</dc:creator>
<dc:creator>Michael D Seckeler</dc:creator>
<dc:creator>Holly Bauser-Heaton</dc:creator>
<dc:creator>Matthew C Schwartz</dc:creator>
<dc:creator>Paul Tannous</dc:creator>
<dc:creator>Cameron Seaman</dc:creator>
<dc:creator>Wendy Whiteside</dc:creator>
<dc:creator>George T Nicholson</dc:creator>
<dc:creator>Priti M Patel</dc:creator>
<dc:creator>Brent M Gordon</dc:creator>
<dc:creator>Ryan A Romans</dc:creator>
<dc:creator>Rajiv Devanagondi</dc:creator>
<dc:creator>Carrie E Herbert</dc:creator>
<dc:creator>Sarosh P Batlivala</dc:creator>
<dc:creator>Brian Boe</dc:creator>
<dc:creator>Gurumurthy Hiremath</dc:creator>
<dc:creator>Jeffrey D Zampi</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>Hybrid Versus Percutaneous Left Atrial Decompression in Infants With Hypoplastic Left Heart Variants and an Intact or Highly Restrictive Atrial Septum: A Multicenter PICES Study</dc:title>
<dc:identifier>pmid:40100953</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.124.014243</dc:identifier>
</item>
<item>
<title>PCI for Surgically Ineligible Patients: Another Piece of the Jigsaw</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100952/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar;18(3):e015200. doi: 10.1161/CIRCINTERVENTIONS.125.015200. Epub 2025 Mar 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100952/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40100952</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.125.015200>10.1161/CIRCINTERVENTIONS.125.015200</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100952</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Tim Kinnaird</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>PCI for Surgically Ineligible Patients: Another Piece of the Jigsaw</dc:title>
<dc:identifier>pmid:40100952</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.125.015200</dc:identifier>
</item>
<item>
<title>Temporal Changes in Procedural Success and Clinical Outcomes of MTEER by Mechanism of MR: Analysis of the STS/TVT Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100951/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The application of mitral transcatheter edge-to-edge repair for nondegenerative etiologies increased considerably. While the odds of technical success were higher for all etiologies except acute ischemic MR, a similar 1-year mortality risk was observed in nondegenerative etiologies compared with DMR in real-world settings. These data support the use of mitral transcatheter edge-to-edge repair in degenerative and nondegenerative etiologies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar;18(3):e014819. doi: 10.1161/CIRCINTERVENTIONS.124.014819. Epub 2025 Mar 18.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: With the expansion of indications for mitral transcatheter edge-to-edge repair into nondegenerative etiologies, it is unknown whether changes in technical success and clinical outcomes have occurred.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/TVT) registry was analyzed from 2013 to 2023. Patients in shock were excluded. Patients were grouped by the mechanism of mitral regurgitation (MR) and divided into time periods.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 68 028 patients were included. The application of mitral transcatheter edge-to-edge repair has evolved over the past decade to include more nondegenerative etiologies-increasing from 19% to 43%. The biggest growth was observed in functional MR (atrial and ventricular). Excluding acute ischemic MR, the odds of technical success were significantly higher for all mechanisms compared with degenerative MR (DMR). Over time more procedures were performed using only 1 implanted device (64.7% during 2022-2023 versus 54.6% during 2013-2017), without negatively impacting technical success. In multivariable analyses, the risk of 1-year heart failure readmission for ventricular functional MR was not higher than for DMR (<i>P</i>=0.10642), while patients with chronic ischemic MR and atrial MR had a 19% higher risk of 1-year heart failure readmission compared with DMR (<i>P</i>=0.00493) even if they had a successful procedure. However, the risk of 1-year mortality was not higher in nondegenerative etiologies compared with DMR. There was no statistically significant interaction between MR mechanism and time in outcomes analyses, indicating that the effect of MR mechanism on the technical and 1-year clinical outcomes did not vary significantly over time.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The application of mitral transcatheter edge-to-edge repair for nondegenerative etiologies increased considerably. While the odds of technical success were higher for all etiologies except acute ischemic MR, a similar 1-year mortality risk was observed in nondegenerative etiologies compared with DMR in real-world settings. These data support the use of mitral transcatheter edge-to-edge repair in degenerative and nondegenerative etiologies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100951/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40100951</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014819>10.1161/CIRCINTERVENTIONS.124.014819</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100951</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Zach Rozenbaum</dc:creator>
<dc:creator>Sreekanth Vemulapalli</dc:creator>
<dc:creator>Miloni Shah</dc:creator>
<dc:creator>Andrzej Stanislaw Kosinski</dc:creator>
<dc:creator>Eric Gnall</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>Temporal Changes in Procedural Success and Clinical Outcomes of MTEER by Mechanism of MR: Analysis of the STS/TVT Registry</dc:title>
<dc:identifier>pmid:40100951</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.124.014819</dc:identifier>
</item>
<item>
<title>Impact of Bypass Conduit and Early Technical Failure on Revascularization for Chronic Limb-Threatening Ischemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100950/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Analysis of as-treated outcomes from the BEST-CLI trial demonstrates the safety and clinical superiority of bypass with SSGSV among patients with CLTI who were deemed suitable for either open surgical bypass or ENDO revascularization. Assessment of great saphenous vein quality should be incorporated into the evaluation of patients with CLTI who are surgical candidates.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar;18(3):e014716. doi: 10.1161/CIRCINTERVENTIONS.124.014716. Epub 2025 Mar 18.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The optimal strategy for lower extremity revascularization (surgical bypass versus endovascular intervention) in patients with chronic limb-threatening ischemia (CLTI) is unclear. We examined the effectiveness of open surgical bypass using single-segment great saphenous vein conduit (SSGSV), alternative conduits (AC), or endovascular interventions (ENDO) among patients with CLTI deemed acceptable for either open surgical bypass or ENDO treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a planned as-treated analysis of the multicenter BEST-CLI (Best Endovascular Versus Best Surgical Therapy in Patients With Critical Limb Ischemia) randomized controlled trial comparing open surgical bypass and ENDO for CLTI due to infrainguinal peripheral artery disease. Outcomes were tabulated based on the initial revascularization received: SSGSV bypass, AC bypass, and ENDO. Analyses were performed for all treated patients and then excluding those who experienced early technical failure. Multivariable Cox regression models were used. End points included the primary trial outcome (major adverse limb event [MALE] or all-cause death), major amputation, MALE at any time or perioperative (30-day) death, reintervention-amputation-death, and all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 1780 patients with CLTI, treatments received included SSGSV bypass (n=621), AC bypass (n=236), and ENDO (n=923) procedures. There were no significant differences in 30-day mortality, major adverse cardiovascular events, or serious adverse events; subjects treated with ENDO experienced greater MALE within 30 days (13.1% versus 2.7%, 3% for SSGSV, AC; <i>P</i>&lt;0.001). On risk-adjusted analysis, SSGSV bypass was associated with reduced MALE or all-cause death (hazard ratio, 0.65 [95% CI, 0.56-0.76]; <i>P</i>&lt;0.001), major amputation (hazard ratio, 0.70 [95% CI, 0.52-0.94]; <i>P</i>=0.017), MALE or perioperative death (hazard ratio, 0.51 [0.41-0.62]; <i>P</i>&lt;0.001), and reintervention-amputation-death (hazard ratio, 0.69 [95% CI, 0.61-0.79]; <i>P</i>&lt;0.001). AC bypass was associated with reduced MALE or perioperative death and reintervention-amputation-death compared with ENDO. Significant benefits of SSGSV over ENDO remained when excluding patients who experienced early technical failure. There were no significant differences in long-term mortality by initial treatment received. When analyzed by the level of disease treated, the improved outcomes of SSGSV were greatest among patients who underwent femoropopliteal revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Analysis of as-treated outcomes from the BEST-CLI trial demonstrates the safety and clinical superiority of bypass with SSGSV among patients with CLTI who were deemed suitable for either open surgical bypass or ENDO revascularization. Assessment of great saphenous vein quality should be incorporated into the evaluation of patients with CLTI who are surgical candidates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT02060630 and NCT02060630.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100950/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40100950</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014716>10.1161/CIRCINTERVENTIONS.124.014716</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100950</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Michael S Conte</dc:creator>
<dc:creator>Alik Farber</dc:creator>
<dc:creator>Andrew Barleben</dc:creator>
<dc:creator>Emiliano Chisci</dc:creator>
<dc:creator>Gheorghe Doros</dc:creator>
<dc:creator>Vikram S Kashyap</dc:creator>
<dc:creator>Ahmed Kayssi</dc:creator>
<dc:creator>Philippe Kolh</dc:creator>
<dc:creator>Carla C Moreira</dc:creator>
<dc:creator>Timothy Nypaver</dc:creator>
<dc:creator>Kenneth Rosenfield</dc:creator>
<dc:creator>Vincent L Rowe</dc:creator>
<dc:creator>Andres Schanzer</dc:creator>
<dc:creator>Niten Singh</dc:creator>
<dc:creator>Jeffrey J Siracuse</dc:creator>
<dc:creator>Michael B Strong</dc:creator>
<dc:creator>Matthew T Menard</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>Impact of Bypass Conduit and Early Technical Failure on Revascularization for Chronic Limb-Threatening Ischemia</dc:title>
<dc:identifier>pmid:40100950</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.124.014716</dc:identifier>
</item>
<item>
<title>Characteristics and Outcomes of PCI Among Patients Ineligible for Surgical Revascularization in the Veterans Affairs Healthcare System</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100949/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Ineligibility for surgical revascularization was associated with increased risk of long-term mortality after PCI. The risk of adverse outcomes after PCI, however, was similar among surgically eligible and ineligible patients after adjusting for measured comorbidities, coronary anatomic features, and procedural complexity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar;18(3):e014899. doi: 10.1161/CIRCINTERVENTIONS.124.014899. Epub 2025 Mar 18.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Ineligibility for surgical revascularization is increasingly prevalent and associated with increased mortality after percutaneous coronary intervention (PCI). High-quality, contemporary, multicenter data regarding clinical outcomes after PCI is scarce and poses a barrier to clinical decision-making for surgically ineligible patients. The aim of this study was to describe and compare the clinical characteristics, institutional variation, and longitudinal outcomes of PCI among surgically eligible and ineligible patients in the Veterans Affairs Healthcare System.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with left main and/or multivessel coronary artery disease undergoing index PCI between October 1, 2017 and September 30, 2022 were identified and the prevalence of surgical ineligibility determined by review of the electronic medical record. The association between surgical ineligibility and mortality and major adverse cardiovascular events (MACE; death, myocardial infarction, repeat revascularization, and stroke) was assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 6192 patients with left main and/or multivessel coronary artery disease (842 surgically ineligible and 5350 surgically eligible) underwent PCI during the study period. After adjustment, surgical ineligibility was associated with a significantly decreased time to mortality (time ratio, 0.801 [95% CI, 0.662-0.970]) over a median 1045-day (interquartile range, 583-1600) follow-up period, though not associated with composite MACE (time ratio, 0.859 [95% CI, 0.685-1.078]). After adjustment for target lesion characteristics and procedural complexity, the association between surgical ineligibility and mortality was attenuated (time ratio, 0.842 [95% CI, 0.688-1.030]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Ineligibility for surgical revascularization was associated with increased risk of long-term mortality after PCI. The risk of adverse outcomes after PCI, however, was similar among surgically eligible and ineligible patients after adjusting for measured comorbidities, coronary anatomic features, and procedural complexity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100949/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40100949</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014899>10.1161/CIRCINTERVENTIONS.124.014899</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100949</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Christopher P Kovach</dc:creator>
<dc:creator>Jerry Lipinski</dc:creator>
<dc:creator>Elise C Mesenbring</dc:creator>
<dc:creator>Peter Boulos</dc:creator>
<dc:creator>Abby Pribish</dc:creator>
<dc:creator>Michael Sola</dc:creator>
<dc:creator>Thomas J Glorioso</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>Robert W Yeh</dc:creator>
<dc:creator>Stephen W Waldo</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>Characteristics and Outcomes of PCI Among Patients Ineligible for Surgical Revascularization in the Veterans Affairs Healthcare System</dc:title>
<dc:identifier>pmid:40100949</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.124.014899</dc:identifier>
</item>
<item>
<title>Intravascular Imaging-Guided Versus Angiography-Guided Complex PCI in Patients With High Bleeding Risk: A Secondary Analysis of the RENOVATE-COMPLEX PCI Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100948/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Patients with HBR were associated with an increased risk of adverse cardiovascular events after complex PCI compared with those without HBR. Intravascular imaging-guided PCI showed a lower risk of the target vessel failure without significant interaction between treatment strategy and the presence of HBR in patients undergoing complex PCI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar;18(3):e014952. doi: 10.1161/CIRCINTERVENTIONS.124.014952. Epub 2025 Mar 18.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Although patients with high bleeding risk (HBR) often have complex coronary artery lesions, it is not known whether intravascular imaging-guided percutaneous coronary intervention (PCI) improves their prognosis. We sought to investigate the benefit of intravascular imaging-guided PCI for complex coronary artery lesions in patients with HBR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a secondary analysis of the RENOVATE-COMPLEX-PCI trial (Randomized Controlled Trial of Intravascular Imaging Guidance Versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention) in which patients with complex coronary artery lesions undergoing PCI were enrolled at 20 sites in Korea from May 2018 through May 2021. Patients were randomized to receive intravascular imaging-guided PCI or angiography-guided PCI and classified according to the presence of HBR. The primary end point was target vessel failure, which was a composite of cardiac death, target vessel-related myocardial infarction, or clinically driven target vessel revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 1639 trial population, 478 patients met HBR criteria. There was no significant difference in the risk of the primary end point between HBR and non-HBR patients (11.8% versus 8.2%; adjusted hazard ratio [HR], 1.05 [95% CI, 0.72-1.54]; <i>P</i>=0.790). However, patients with HBR were at higher risk for cardiac death or spontaneous target vessel-related myocardial infarction (adjusted HR, 2.04 [95% CI, 1.09-3.80]; <i>P</i>=0.025), all-cause death (adjusted HR, 3.30 [95% CI, 1.93-5.62]; <i>P</i>&lt;0.001), and cardiac death (adjusted HR, 2.36 [95% CI, 1.10-5.09]; <i>P</i>=0.028). Intravascular imaging-guided PCI showed a lower risk of the primary end point compared with angiography-guided PCI in both HBR patients (9.7% versus 15.8%; adjusted HR, 0.57 [95% CI, 0.31-1.02]; <i>P</i>=0.060) and non-HBR patients (6.9% versus 10.8%; adjusted HR, 0.65 [95% CI, 0.43-0.99]; <i>P</i>=0.045), without significant interaction (<i>P</i> for interaction=0.796).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with HBR were associated with an increased risk of adverse cardiovascular events after complex PCI compared with those without HBR. Intravascular imaging-guided PCI showed a lower risk of the target vessel failure without significant interaction between treatment strategy and the presence of HBR in patients undergoing complex PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03381872.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100948/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40100948</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014952>10.1161/CIRCINTERVENTIONS.124.014952</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100948</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Jinhwan Jo</dc:creator>
<dc:creator>Sang Yoon Lee</dc:creator>
<dc:creator>Woochan Kwon</dc:creator>
<dc:creator>Seung-Jae Lee</dc:creator>
<dc:creator>Jong-Young Lee</dc:creator>
<dc:creator>Seung Hun Lee</dc:creator>
<dc:creator>Doosup Shin</dc:creator>
<dc:creator>Sang Min Kim</dc:creator>
<dc:creator>Kyeong Ho Yun</dc:creator>
<dc:creator>Jae Young Cho</dc:creator>
<dc:creator>Chan Joon Kim</dc:creator>
<dc:creator>Hyo-Suk Ahn</dc:creator>
<dc:creator>Chang-Wook Nam</dc:creator>
<dc:creator>Hyuck-Jun Yoon</dc:creator>
<dc:creator>Yong Hwan Park</dc:creator>
<dc:creator>Wang Soo Lee</dc:creator>
<dc:creator>Ki Hong Choi</dc:creator>
<dc:creator>Taek Kyu Park</dc:creator>
<dc:creator>Jeong Hoon Yang</dc:creator>
<dc:creator>Seung-Hyuk Choi</dc:creator>
<dc:creator>Hyeon-Cheol Gwon</dc:creator>
<dc:creator>Young Bin Song</dc:creator>
<dc:creator>Joo-Yong Hahn</dc:creator>
<dc:creator>Sang Yeub Lee</dc:creator>
<dc:creator>Joo Myung Lee</dc:creator>
<dc:creator>RENOVATE-COMPLEX-PCI Investigators</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>Intravascular Imaging-Guided Versus Angiography-Guided Complex PCI in Patients With High Bleeding Risk: A Secondary Analysis of the RENOVATE-COMPLEX PCI Trial</dc:title>
<dc:identifier>pmid:40100948</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.124.014952</dc:identifier>
</item>
<item>
<title>Prognosis and Risk Stratification in Dilated Cardiomyopathy With LVEF≤35%: Cardiac MRI Insights for Better Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100943/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Patients with dilated cardiomyopathy with late gadolinium enhancement≥7.5% were at heightened risk of SCD events, which can be used for risk assessment. Risk stratifications for SCD, combining clinical and cardiac magnetic resonance imaging may potentially guide decision-making for implantable cardioverter defibrillator therapy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Imaging. 2025 Mar;18(3):e017246. doi: 10.1161/CIRCIMAGING.124.017246. Epub 2025 Mar 18.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Current guidelines recommend implantable cardioverter defibrillators for the primary prevention of sudden cardiac death (SCD) in patients with dilated cardiomyopathy with left ventricular ejection fraction (LVEF)≤35%. However, its effectiveness is hindered by the inability to reliably discriminate between the risk of SCD and competing death of heart failure deterioration, thereby limiting its clinical utility. We aimed to refine the SCD risk stratification model based on cardiac magnetic resonance imaging for patients with dilated cardiomyopathy with LVEF≤35%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 1272 patients with dilated cardiomyopathy with LVEF≤35% who underwent cardiac magnetic resonance imaging were consecutively enrolled in this study. The primary end point is a composite of SCD or aborted SCD and the second end point is a composite of heart failure death and heart transplantation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over a median follow-up of 86.3 months, 101 patients reached the primary end point. In the adjusted analysis, age (hazard ratio [HR], 1.02 [95% CI, 1.01-1.04]; <i>P</i>=0.006) years, a family history of SCD (HR, 2.00 [95% CI, 1.01-3.98]; <i>P</i>=0.05), NT-proBNP (N-terminal pro-B-type natriuretic peptide) (HR, 2.02 [95% CI, 1.18-3.44]; <i>P</i>=0.01), LVEF (per 5% HR, 0.79 [95% CI, 0.66-0.95]; <i>P</i>=0.01), and late gadolinium enhancement≥7.5% (HR, 4.11[95% CI, 2.72-6.21]; <i>P</i>&lt;0.001) were associated with SCD or aborted SCD. Left atrial volume index≥68.3 mL/m<sup>2</sup> was an independent predictor of the secondary end point (adjusted HR, 1.65 [95% CI, 1.13-2.40]; <i>P</i>=0.009). Compared with late gadolinium enhancement&lt;7.5%, patients with late gadolinium enhancement≥7.5% and LVEF≤20% had a 7.12-fold higher risk of experiencing SCD events in competing Cox analysis (annual event rate, 4.8%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with dilated cardiomyopathy with late gadolinium enhancement≥7.5% were at heightened risk of SCD events, which can be used for risk assessment. Risk stratifications for SCD, combining clinical and cardiac magnetic resonance imaging may potentially guide decision-making for implantable cardioverter defibrillator therapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100943/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40100943</a> | DOI:<a href=https://doi.org/10.1161/CIRCIMAGING.124.017246>10.1161/CIRCIMAGING.124.017246</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100943</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Di Zhou</dc:creator>
<dc:creator>Leyi Zhu</dc:creator>
<dc:creator>Shuang Li</dc:creator>
<dc:creator>Weichun Wu</dc:creator>
<dc:creator>Baiyan Zhuang</dc:creator>
<dc:creator>Jing Xu</dc:creator>
<dc:creator>Wenjing Yang</dc:creator>
<dc:creator>Jian He</dc:creator>
<dc:creator>Yining Wang</dc:creator>
<dc:creator>Yuhui Zhang</dc:creator>
<dc:creator>Guanshu Liu</dc:creator>
<dc:creator>Xiaoxin Sun</dc:creator>
<dc:creator>Qiang Zhang</dc:creator>
<dc:creator>Zhongzhao Teng</dc:creator>
<dc:creator>Arlene Sirajuddin</dc:creator>
<dc:creator>Andrew E Arai</dc:creator>
<dc:creator>Shihua Zhao</dc:creator>
<dc:creator>Minjie Lu</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular imaging</dc:source>
<dc:title>Prognosis and Risk Stratification in Dilated Cardiomyopathy With LVEF≤35%: Cardiac MRI Insights for Better Outcomes</dc:title>
<dc:identifier>pmid:40100943</dc:identifier>
<dc:identifier>doi:10.1161/CIRCIMAGING.124.017246</dc:identifier>
</item>
<item>
<title>Can We Make the Next Step in Precision Risk Stratification of Dilated Cardiomyopathy?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100942/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Imaging. 2025 Mar;18(3):e018057. doi: 10.1161/CIRCIMAGING.125.018057. Epub 2025 Mar 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100942/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40100942</a> | DOI:<a href=https://doi.org/10.1161/CIRCIMAGING.125.018057>10.1161/CIRCIMAGING.125.018057</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100942</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Viren Ahluwalia</dc:creator>
<dc:creator>Brian P Halliday</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular imaging</dc:source>
<dc:title>Can We Make the Next Step in Precision Risk Stratification of Dilated Cardiomyopathy?</dc:title>
<dc:identifier>pmid:40100942</dc:identifier>
<dc:identifier>doi:10.1161/CIRCIMAGING.125.018057</dc:identifier>
</item>
<item>
<title>Cognitive Function and Patient-Reported Outcomes After Cardiogenic Shock</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100175/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 10:S0735-1097(25)00483-8. doi: 10.1016/j.jacc.2025.02.023. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100175/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40100175</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.023>10.1016/j.jacc.2025.02.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100175</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Eric J Hall</dc:creator>
<dc:creator>Jeff Schaffert</dc:creator>
<dc:creator>Sachin Agarwal</dc:creator>
<dc:creator>Colby R Ayers</dc:creator>
<dc:creator>Alexandra V Sykes</dc:creator>
<dc:creator>Laura H Lacritz</dc:creator>
<dc:creator>Amil M Shah</dc:creator>
<dc:creator>E Wesley Ely</dc:creator>
<dc:creator>C Munro Cullum</dc:creator>
<dc:creator>Maryjane A Farr</dc:creator>
<dc:creator>James A de Lemos</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cognitive Function and Patient-Reported Outcomes After Cardiogenic Shock</dc:title>
<dc:identifier>pmid:40100175</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.023</dc:identifier>
</item>
<item>
<title>2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock: A Report of the American College of Cardiology Solution Set Oversight Committee</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100174/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 12:S0735-1097(25)00418-8. doi: 10.1016/j.jacc.2025.02.018. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100174/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40100174</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.018>10.1016/j.jacc.2025.02.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100174</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Shashank S Sinha</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:creator>Navin K Kapur</dc:creator>
<dc:creator>Rachna Kataria</dc:creator>
<dc:creator>Robert O Roswell</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock: A Report of the American College of Cardiology Solution Set Oversight Committee</dc:title>
<dc:identifier>pmid:40100174</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.018</dc:identifier>
</item>
<item>
<title>Managing Cardiogenic Shock Caused by Acute Myocardial Infarction: Invisible Challenges Revealed in a Statewide Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100173/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 10:S0735-1097(25)05209-X. doi: 10.1016/j.jacc.2025.02.027. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100173/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40100173</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.027>10.1016/j.jacc.2025.02.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100173</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Eric P Cantey</dc:creator>
<dc:creator>Aaron Lopacinski</dc:creator>
<dc:creator>Milan Seth</dc:creator>
<dc:creator>David E Hamilton</dc:creator>
<dc:creator>Elias J Dayoub</dc:creator>
<dc:creator>Siddharth Gandhi</dc:creator>
<dc:creator>Mir B Basir</dc:creator>
<dc:creator>Amir Kaki</dc:creator>
<dc:creator>Ryan D Madder</dc:creator>
<dc:creator>Devraj Sukul</dc:creator>
<dc:creator>Hitinder S Gurm</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Managing Cardiogenic Shock Caused by Acute Myocardial Infarction: Invisible Challenges Revealed in a Statewide Registry</dc:title>
<dc:identifier>pmid:40100173</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.027</dc:identifier>
</item>
<item>
<title>Respiratory Syncytial Virus and Incidence of Cardiovascular Events: A Nationwide Self-Controlled Case Series Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100172/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 10:S0735-1097(25)05260-X. doi: 10.1016/j.jacc.2025.02.031. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100172/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40100172</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.031>10.1016/j.jacc.2025.02.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100172</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Mats C Højbjerg Lassen</dc:creator>
<dc:creator>Daniel Modin</dc:creator>
<dc:creator>Niklas Dyrby Johansen</dc:creator>
<dc:creator>Pradeesh Sivapalan</dc:creator>
<dc:creator>Anders Hviid</dc:creator>
<dc:creator>Tyra Grove Krause</dc:creator>
<dc:creator>Jens Ulrik Stæhr Jensen</dc:creator>
<dc:creator>Tor Biering-Sørensen</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Respiratory Syncytial Virus and Incidence of Cardiovascular Events: A Nationwide Self-Controlled Case Series Analysis</dc:title>
<dc:identifier>pmid:40100172</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.031</dc:identifier>
</item>
<item>
<title>Best Practices for Transforming Cardiovascular Care Delivery and Implementation: A Modern Framework</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100171/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 10:S0735-1097(25)00468-1. doi: 10.1016/j.jacc.2025.02.020. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100171/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40100171</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.02.020>10.1016/j.jacc.2025.02.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100171</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Ami B Bhatt</dc:creator>
<dc:creator>Ginger K Biesbrock</dc:creator>
<dc:creator>Cathleen Biga</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Best Practices for Transforming Cardiovascular Care Delivery and Implementation: A Modern Framework</dc:title>
<dc:identifier>pmid:40100171</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.02.020</dc:identifier>
</item>
<item>
<title>Systolic Blood Pressure and Cardiovascular Mortality in U.S. Adults Aged 80+ Taking Antihypertensive Medications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100170/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 26:S0735-1097(25)00335-3. doi: 10.1016/j.jacc.2025.01.033. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100170/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40100170</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.01.033>10.1016/j.jacc.2025.01.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100170</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Huanhuan Yang</dc:creator>
<dc:creator>Chenxi Huang</dc:creator>
<dc:creator>Mitsuaki Sawano</dc:creator>
<dc:creator>Jeph Herrin</dc:creator>
<dc:creator>Guochong Chen</dc:creator>
<dc:creator>Zhihui Li</dc:creator>
<dc:creator>Erica S Spatz</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:creator>Yuan Lu</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Systolic Blood Pressure and Cardiovascular Mortality in U.S. Adults Aged 80+ Taking Antihypertensive Medications</dc:title>
<dc:identifier>pmid:40100170</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.01.033</dc:identifier>
</item>
<item>
<title>Use of Cardiac Rehabilitation in Older Patients with Myocardial Infarction Complicated by Cardiogenic Shock</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40099778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 12:S0735-1097(25)05893-0. doi: 10.1016/j.jacc.2025.03.497. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40099778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40099778</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.497>10.1016/j.jacc.2025.03.497</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40099778</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Mohammed Essa</dc:creator>
<dc:creator>Sérgio R R Decker</dc:creator>
<dc:creator>Lichen Liang</dc:creator>
<dc:creator>Yang Song</dc:creator>
<dc:creator>Merilyn S Varghese</dc:creator>
<dc:creator>Jose F Figueroa</dc:creator>
<dc:creator>Laurence Sperling</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Steven J Keteyian</dc:creator>
<dc:creator>Michael P Thompson</dc:creator>
<dc:creator>Alexis Beatty</dc:creator>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Use of Cardiac Rehabilitation in Older Patients with Myocardial Infarction Complicated by Cardiogenic Shock</dc:title>
<dc:identifier>pmid:40099778</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.497</dc:identifier>
</item>
<item>
<title>Effect of Targeting apoC-III with Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40099777/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION: Plozasiran induced reductions in apoC-III and showed potentially favorable quantitative and qualitative changes in lipoproteins as assessed by NMR in patients with hypertriglyceridemia and mixed hyperlipidemia. Plozasiran reduced TRL-P by ∼50%, shifted LDL to larger particles, and modestly increased HDL-P concentration. While high-potency TRL-lowering therapies can lead to an overall LDL-C increase, plozasiran did not increase LDL-P or apoB but shifted LDL particle size distribution...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 12:S0735-1097(25)05892-9. doi: 10.1016/j.jacc.2025.03.496. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Plozasiran, an investigational siRNA targeting hepatic apoC-III, reduces triglyceride-rich lipoproteins (TRLs). The impact of plozasiran on lipoprotein particle numbers and sizes is unknown. However, reductions in the number of TRL particles (TRL-P) and a shift to possibly less atherogenic large low-density lipoprotein particles (LDL-P) are expected.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To determine the impact of plozasiran on lipoprotein particle concentration and subclass distribution using nuclear magnetic resonance (NMR) in two phase 2 studies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients (N=403) from SHASTA-2 (severe hypertriglyceridemia) and MUIR (mixed hyperlipidemia) were administered 2 total subcutaneous doses of plozasiran (10, 25, or 50 mg) or placebo at baseline and week 12. Comprehensive lipoprotein profiling was conducted with NMR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In SHASTA-2, there was a dose-dependent reduction in TRL-P, with placebo-adjusted total TRL-P reductions of -46% and reductions across all TRL subclasses with plozasiran. While total LDL-P was unchanged, large LDL-P concentration increased by +53% and medium by +56%; small LDL-P trended lower (-13%). Total HDL-P increased by +8%, primarily driven by a +36% increase in large high-density lipoprotein particles (HDL-P). Similarly, in MUIR, there were dose-dependent reductions in TRL-P, with total TRL-P significantly reduced by -48% (pooled plozasiran) and reductions across all TRL subclasses with plozasiran. While total LDL-P was unchanged, large and medium LDL-P levels increased by +88% and +46%, respectively; small LDL-P levels decreased by -28%. Total HDL-P increased by +12%, driven by a +83% increase in large HDL-P.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: Plozasiran induced reductions in apoC-III and showed potentially favorable quantitative and qualitative changes in lipoproteins as assessed by NMR in patients with hypertriglyceridemia and mixed hyperlipidemia. Plozasiran reduced TRL-P by ∼50%, shifted LDL to larger particles, and modestly increased HDL-P concentration. While high-potency TRL-lowering therapies can lead to an overall LDL-C increase, plozasiran did not increase LDL-P or apoB but shifted LDL particle size distribution from small dense LDL towards larger sizes. The ∼50% reduction in TRL-P with no increase in apoB and possibly beneficial qualitative changes in LDL suggests the potential of plozasiran to lower cardiovascular risk, which may be evaluated in a prospective outcomes trial.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40099777/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40099777</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.496>10.1016/j.jacc.2025.03.496</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40099777</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>Daniel Gaudet</dc:creator>
<dc:creator>Robert S Rosenson</dc:creator>
<dc:creator>Robert A Hegele</dc:creator>
<dc:creator>Rong Zhou</dc:creator>
<dc:creator>Stacey Melquist</dc:creator>
<dc:creator>Jennifer Hellawell</dc:creator>
<dc:creator>Nicholas J Leeper</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effect of Targeting apoC-III with Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia</dc:title>
<dc:identifier>pmid:40099777</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.496</dc:identifier>
</item>
<item>
<title>Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis with Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40099776/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Vutrisiran demonstrated evidence of benefit across the range of baseline disease severities in HELIOS-B, with the greatest benefit in earlier, less severe disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 11:S0735-1097(25)05823-1. doi: 10.1016/j.jacc.2025.03.477. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Vutrisiran reduced the risk of all-cause mortality (ACM) and recurrent cardiovascular (CV) events in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in HELIOS-B (NCT04153149).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To assess the effect of vutrisiran in HELIOS-B patients with different heart failure severities.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: HELIOS-B randomized ATTR-CM patients with NYHA class I-III (class IV or class III with National Amyloidosis Centre [NAC] stage III were excluded) 1:1 to vutrisiran 25 mg or placebo every 3 months for up to 36 months. This exploratory subgroup analysis assessed the primary composite endpoint of ACM and recurrent CV events, ACM, and additional functional and biomarker endpoints.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 654 patients, 84 (13%), 508 (78%), and 62 (9%) were in NYHA class I, II, and III, respectively. Median baseline NT-proBNP level was 1,920 ng/L. Lower risk of ACM and recurrent CV events was observed with vutrisiran versus placebo across baseline severity subgroups: Respective hazard ratios (95% CIs): 0.54 (0.27, 1.10), 0.77 (0.57, 1.03), and 0.68 (0.33, 1.41) in NYHA class I, II, and III,; 0.52 (0.30, 0.88), 0.61 (0.37, 1.00) and 0.93 (0.64, 1.35) in NT-proBNP tertiles (&lt;1,368 ng/L, ≥1,368 and &lt; 2,691 ng/L and ≥2,691 ng/L); 0.49 (0.34, 0.72) and 1.07 (0.74, 1.56) in NAC Stage I and II/III; and 0.69 (0.45, 1.07) and 0.74 (0.53, 1.02) in Columbia early and intermediate/late stage. Similar effects were observed in the monotherapy population (patients not on tafamidis at baseline) and across the additional endpoints evaluated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Vutrisiran demonstrated evidence of benefit across the range of baseline disease severities in HELIOS-B, with the greatest benefit in earlier, less severe disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40099776/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40099776</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.477>10.1016/j.jacc.2025.03.477</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40099776</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Mathew S Maurer</dc:creator>
<dc:creator>Ronald M Witteles</dc:creator>
<dc:creator>Pablo Garcia-Pavia</dc:creator>
<dc:creator>Farooq H Sheikh</dc:creator>
<dc:creator>Caroline Morbach</dc:creator>
<dc:creator>Daniel Rodriguez Duque</dc:creator>
<dc:creator>Emre Aldinc</dc:creator>
<dc:creator>Satish A Eraly</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis with Cardiomyopathy</dc:title>
<dc:identifier>pmid:40099776</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.477</dc:identifier>
</item>
<item>
<title>More Than an Infant's Respiratory Illness: The Unfolding Cardiovascular Consequences of RSV in Older Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40099775/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 6:S0735-1097(25)05338-0. doi: 10.1016/j.jacc.2025.03.007. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40099775/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40099775</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.007>10.1016/j.jacc.2025.03.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40099775</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Pekka J Vartiainen</dc:creator>
<dc:creator>Yuan Huang</dc:creator>
<dc:creator>Mitsuaki Sawano</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>More Than an Infant's Respiratory Illness: The Unfolding Cardiovascular Consequences of RSV in Older Adults</dc:title>
<dc:identifier>pmid:40099775</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.007</dc:identifier>
</item>
<item>
<title>Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40099774/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Vutrisiran maintained or improved functional capacity, health status, and QOL in more patients with ATTR-CM versus placebo over 30 months.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Mar 8:S0735-1097(25)05796-1. doi: 10.1016/j.jacc.2025.03.454. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) progressively impairs functional capacity, health status, and quality of life (QOL). In HELIOS-B, vutrisiran reduced all-cause mortality and recurrent cardiovascular events compared with placebo in patients with ATTR-CM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To further analyze vutrisiran's efficacy on functional capacity, health status, and QOL.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients were randomized 1:1 to receive vutrisiran 25 mg or placebo every 12 weeks up to 36 months. 6-minute walk test (6-MWT) and Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) were completed at baseline and every 6 months. Cutoff values for worsening were a decrease from baseline of >;7 m, >;15 m, and >;35 m (6-MWT), and >;5 and >;10 points (KCCQ-OS). Additionally, change from baseline was analyzed in prespecified subgroups and KCCQ subdomains.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the overall population at Month 30, greater proportions of patients treated with vutrisiran versus placebo had maintained or improved 6-MWT distance according to all cutoffs analyzed (>;7 m [49.6% vs 33.2%], >;15 m [55.5% vs 38.6%], and >;35 m [68.4% vs 51.6%]; all P&lt;0.001). Similarly, greater proportions of patients experienced maintenance or improvement in KCCQ-OS according to cutoff values (>;5 points [63.5% vs 46.6%; P&lt;0.001], >;10 points [74.6% vs 60.7%; P&lt;0.01]). Additionally, least squares (LS) mean difference in change from baseline in KCCQ subdomains, and in 6-MWT and KCCQ-OS across prespecified subgroups, favored vutrisiran versus placebo. Benefits observed with vutrisiran were similar in the monotherapy population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Vutrisiran maintained or improved functional capacity, health status, and QOL in more patients with ATTR-CM versus placebo over 30 months.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40099774/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40099774</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2025.03.454>10.1016/j.jacc.2025.03.454</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40099774</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Farooq H Sheikh</dc:creator>
<dc:creator>Gilbert Habib</dc:creator>
<dc:creator>W H Wilson Tang</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:creator>Ugochukwu O Egolum</dc:creator>
<dc:creator>Simone Longhi</dc:creator>
<dc:creator>Chongshu Chen</dc:creator>
<dc:creator>Emre Aldinc</dc:creator>
<dc:creator>Marianna Fontana</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy</dc:title>
<dc:identifier>pmid:40099774</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2025.03.454</dc:identifier>
</item>
<item>
<title>Nrf3-Mediated Mitochondrial Superoxide Promotes Cardiomyocyte Apoptosis and Impairs Cardiac Functions by Suppressing Pitx2</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40099370/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319001344&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Nrf3 promotes injury-induced CM apoptosis and deteriorates cardiac functions by increasing mitochondrial ROS production through suppressing Pitx2 expression. Targeting the Nrf3-Pitx2-mitochondrial ROS signal axis may therefore represent a novel therapeutic approach for MI treatment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 18. doi: 10.1161/CIRCULATIONAHA.124.070286. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Myocardial infarction (MI) elicits mitochondria reactive oxygen species (ROS) production and cardiomyocyte (CM) apoptosis. Nrf3 (nuclear factor erythroid 2-related factor 3) has an established role in regulating redox signaling and tissue homeostasis. Here, we aimed to evaluate the role and mechanism of Nrf3 in injury-induced pathological cardiac remodeling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Global (Nrf3-KO) and CM-specific (Nrf3<sup>△CM</sup>) Nrf3 knockout mice were subjected to MI or ischemia/reperfusion injury, followed by functional and histopathological analysis. Primary neonatal mouse and rat ventricular myocytes and CMs derived from human induced pluripotent stem cells were used to evaluate the impact of Nrf3 on CM apoptosis and mitochondrial ROS production. Chromatin immunoprecipitation sequencing and immunoprecipitation-mass spectrometry analysis were used to uncover potential targets of Nrf3. MitoParaquat administration and CM-specific adeno-associated virus vectors were used to further confirm the <i>i</i>n vivo relevance of the identified signal pathways.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Nrf3 was expressed mainly in CMs in healthy human hearts, and an increased level of Nrf3 was observed in CMs within the border zone of infarcted human hearts and murine cardiac tissues after MI. Both global and CM-specific Nrf3 knockout significantly decreased injury-induced mitochondrial ROS production, CM apoptosis, and pathological cardiac remodeling, consequently improving cardiac functions. In addition, cardiac-specific Nrf3 overexpression reversed the ameliorative cardiac phenotypes observed in Nrf3-KO mice. Functional studies showed that Nrf3 promoted neonatal mouse ventricular myocyte, neonatal rat ventricular myocyte, and CMs derived from human induced pluripotent stem cell apoptosis by increasing mitochondrial ROS production. Critically, augmenting mitochondrial ROS with MitoParaquat blunted the beneficial effects of Nrf3 deletion on cardiac function and remodeling. Mechanistically, a redox regulator Pitx2 (paired-like homeodomain transcription factor 2) was identified as one of the main target genes of Nrf3. Specifically, Nrf3 binds to <i>Pitx2</i> promoter, where it increases DNA methylation through recruiting heterogeneous nuclear ribonucleoprotein K and DNA-methyltransferase 1 complex, thereby inhibiting Pitx2 expression. CM-specific knockdown of Pitx2 blunted the beneficial effects of Nrf3 deletion on cardiac function and remodeling, and cardiac-specific Pitx2 overexpression attenuated MI-induced mitochondrial ROS production and CM apoptosis, as well as preserved cardiac functions after MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Nrf3 promotes injury-induced CM apoptosis and deteriorates cardiac functions by increasing mitochondrial ROS production through suppressing Pitx2 expression. Targeting the Nrf3-Pitx2-mitochondrial ROS signal axis may therefore represent a novel therapeutic approach for MI treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40099370/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319001344&v=2.18.0.post9+e462414">40099370</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070286>10.1161/CIRCULATIONAHA.124.070286</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40099370</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Qishan Chen</dc:creator>
<dc:creator>Ancheng Zheng</dc:creator>
<dc:creator>Xiaolei Xu</dc:creator>
<dc:creator>Zhenning Shi</dc:creator>
<dc:creator>Mei Yang</dc:creator>
<dc:creator>Shasha Sun</dc:creator>
<dc:creator>Leyu Wang</dc:creator>
<dc:creator>Yumeng Wang</dc:creator>
<dc:creator>Haige Zhao</dc:creator>
<dc:creator>Qingzhong Xiao</dc:creator>
<dc:creator>Li Zhang</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Nrf3-Mediated Mitochondrial Superoxide Promotes Cardiomyocyte Apoptosis and Impairs Cardiac Functions by Suppressing Pitx2</dc:title>
<dc:identifier>pmid:40099370</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070286</dc:identifier>
</item>





























</channel>
</rss>